FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wen-Kai Weng

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Physiology

Antibody-Dependent Cell Cytotoxicity

Anatomy

Cytokine-Induced Killer Cells

Co-author Network

Publications

TOP 3
Katayoun Rezvani; Wen-Kai Weng; Ranjana Advani; Joshua D Brody; Victoria Carlton; Debra Katherine Czerwinski; Malek Faham; Holbrook E Kohrt; Ronald Levy; Aaron C Logan; Robert S Negrin; John Barrett
Cancer vaccines and T cell therapy.
Sally Arai; Jonathan E Benjamin; Janice Brown; George L Chen; Laura J Johnston; Carol D Jones; Ginna G Laport; Robert Lowsky; Balasubramanian Narasimhan; Robert S Negrin; Jessica Ramirez; Bita Sahaf; Joanna Schaenman; Judith A Shizuru; Wen-Kai Weng; James L Zehnder; David B Miklos
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.
Andy I Chen; Laura J Johnston; Ginna G Laport; Robert Lowsky; A McMillan; David B Miklos; Robert S Negrin; Judith A Shizuru; S Arai; Wen-Kai Weng; Keith E Stockerl-Goldstein
Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wen-Kai Weng (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Katayoun Rezvani; Wen-Kai Weng; Ranjana Advani; Joshua D Brody; Victoria Carlton; Debra Katherine Czerwinski; Malek Faham; Holbrook E Kohrt; Ronald Levy; Aaron C Logan; Robert S Negrin; John Barrett
Cancer vaccines and T cell therapy.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013;19(1 Suppl):S97-S101.
2012: Sally Arai; Jonathan E Benjamin; Janice Brown; George L Chen; Laura J Johnston; Carol D Jones; Ginna G Laport; Robert Lowsky; Balasubramanian Narasimhan; Robert S Negrin; Jessica Ramirez; Bita Sahaf; Joanna Schaenman; Judith A Shizuru; Wen-Kai Weng; James L Zehnder; David B Miklos
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.
Blood 2012;119(25):6145-54.
2012: Andy I Chen; Laura J Johnston; Ginna G Laport; Robert Lowsky; A McMillan; David B Miklos; Robert S Negrin; Judith A Shizuru; S Arai; Wen-Kai Weng; Keith E Stockerl-Goldstein
Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma.
Bone marrow transplantation 2012;47(4):516-21.
2012: Holbrook E Kohrt; Robert W Carlson; Lieping Chen; Michael F Clarke; A Dimitrios Colevas; Debra Czerwinski; Matthew J Goldstein; Roch Houot; Joseph A Mollick; Ferenc Scheeren; Frank E Stockdale; Kipp Weiskopf; Wen-Kai Weng; Ronald Levy
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.
The Journal of clinical investigation 2012;122(3):1066-75.
2011: Ginna G Laport; Robert Lowsky; David Miklos; Sally Arai; Randall Armstrong; Jeanette Baker; Jonathan E Benjamin; Laura J Johnston; Kevin Sheehan; Judith A Shizuru; Wen-Kai Weng; Ruby M Wong; Robert S Negrin
Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2011;17(11):1679-87.
2010: Wen-Kai Weng; Robert S Negrin; Philip W Lavori; Sandra J Horning
Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(2):279-84.
2009: Holbrook E Kohrt; Brit B Turnbull; Kartoosh Heydari; Judith A Shizuru; Ginna G Laport; David B Miklos; Laura J Johnston; Sally Arai; Wen-Kai Weng; Richard T Hoppe; Philip W Lavori; Karl G Blume; Robert S Negrin; Samuel Strober; Robert Lowsky
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.
Blood 2009;114(5):1099-109.
2009: John M Timmerman; Julie M Vose; Debra K Czerwinski; Wen-Kai Weng; Diane Ingolia; Martha Mayo; Dan W Denney; Ronald Levy
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.
Leukemia & lymphoma 2009;50(1):37-46.
2007: Wen-Kai Weng; Debra K Czerwinski; Ronald Levy
Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy.
Blood 2007;109(3):951-3.
2004: Wen-Kai Weng; Debra K Czerwinski; John M Timmerman; Frank J Hsu; Ronald Levy
Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4717-24.
2003: Wen-Kai Weng; Ronald Levy
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(21):3940-7.
2003: Wen-Kai Weng; Shoshana Levy
Hepatitis C virus (HCV) and lymphomagenesis.
Leukemia & lymphoma 2003;44(7):1113-20.
2001: Wen-Kai Weng; Ronald Levy
Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
Blood 2001;98(5):1352-7.